RE:RE:RE:RE:BIOV PapilocareSorry! "Papilocare+" is my speculation on overall strategy. If they get FDA approval as a device (which is likely, as its approved in EU as a device) they can market it w/o need for a prescription so it will be distributed via doctor offices, pharmacies, chain stores, etc. The PALOMA study done by Procare showed very nice efficacy on cervical lesions and nice effect as antiviral on HPV. Am going to guess that the initial US device indication will be for reducing cervical lesions caused by HPV (as it is in EU). But as they are marketing it they can then in parallel make some formulation adjustments and file an IND as a "new" therapeutic for the HPV virus, which can be sold at a much higher price i.e. gives you like a 10x or more on revenue THats the Papilocare + that I refer to. Its a typical product line extension strategy, and since BIOV has prior pharma guys in management , this would make sense.